Biotech Archives - Page 61 of 795

2 minute read

Veracyte’s New Study Shows The Decipher Prostate Test Is Prognostic For Prostate Cancer Progression Among Patients Undergoing Active Surveillance

April 22, 8:42 AM

Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that a new study published in JCO Precision Oncology shows that, among patients undergoing Active Surveillance (AS) for prostate cancer,

VCYT

2 minute read

Waters Accelerates The Development Of Gene-based Therapeutics With New GTxResolve Premier SEC Columns

By Benzinga Newsdesk

April 22, 8:15 AM

New line of GTxResolve™ Premier SEC Columns provide higher sensitivity, resolution, and throughput to accelerate the development of cell & gene-based therapeutics.Reduces problematic non-specific binding,

WAT

2 minute read

AmeriServ Financial Reaches Cooperation Agreement With Significant Shareholder SB Value Partners, L.P.

By Benzinga Newsdesk

April 22, 8:10 AM

AmeriServ Financial, Inc. (NASDAQ:ASRV) ("AmeriServ" or the "Company") today announced that it has reached a cooperation agreement ("Cooperation Agreement") with SB Value Partners, L.P. ("SBV"), which owns approximately

ASRV

2 minute read

Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications Highlighting Natera’s Technology In The Scientific Literature.

By Benzinga Newsdesk

April 22, 8:08 AM

Demonstrates commitment to generating real-world clinical evidence to change disease management and improve patient outcomesNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today

NTRA

1 minute read

Enlivex Announces Dosing Of First Two Patients In Its Randomized, Controlled Phase I/II Trial Evaluating Allocetra In Patients With Knee Osteoarthritis

By Benzinga Newsdesk

April 22, 8:05 AM

Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company")))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the first two patients have been dosed in the Company's

ENLV

2 minute read

Corcept Announces Results From Open-Label Portion Of Pivotal Phase 3 GRACE Trial In Patients With Cushing’s Syndrome

By Benzinga Newsdesk

April 22, 8:03 AM

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by

CORT

1 minute read

EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent

By Vandana Singh

April 22, 8:00 AM

Adial Pharmaceuticals' genetic diagnostic patent, expanding treatment for alcohol and drug dependencies. CEO highlights the significance.

ADIL

2 minute read

Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense

By Vandana Singh

April 22, 7:00 AM

Plus Therapeutics will secure $3 million in funding from the Department of Defense for pediatric brain cancer trial expansion.

PSTV

1 minute read

Hepion Pharmaceuticals Initiates Wind-Down Activities In Phase 2b ‘ASCEND-NASH’ Trial

By Benzinga Newsdesk

April 19, 4:33 PM

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic

HEPA

2 minute read

Infection-Focused Barinthus Bio’s VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives

By Vandana Singh

April 19, 11:49 AM

Explore the latest findings from Barinthus Biotherapeutics on VTP-200's performance in the APOLLO trial for low-grade cervical lesions linked to persistent hrHPV infection. Positive trends were noted, though not statistically significant. No major safety concerns were observed.

BRNS